Form 4 Filing for BridgeBio Pharma, Inc. - Insider Transaction

Andrea Ellis, a director at BridgeBio Pharma, Inc. (BBIO), reported a transaction on June 22, 2026. Ellis acquired 3,990 shares of Common Stock via restricted stock units (RSUs) under the company's 2021 Stock Option and Incentive Plan. These RSUs vest on June 22, 2027, contingent upon continued service. Additionally, Ellis was granted 5,277 stock options, also vesting on June 22, 2027, subject to continued service. The RSU acquisition was a non-derivative transaction with a reported price of $0.00, bringing the post-transaction total to 22,579 shares. The stock option grant, a derivative transaction, also had a $0.00 price per share, with 5,277 shares underlying the option, resulting in a post-transaction ownership of 5,277 shares. The report was signed by Will Solis as Attorney-in-Fact on June 24, 2026.